Covalon Technologies Ltd.

With increasing clinical validation, accelerating sales wins, and expanding business development discussions, Covalon continues to build momentum. Read More: bit.ly/3MPnfOO #MedTech #HealthcareInnovation #EarningsUpdate

Read Full Press Release:bit.ly/3OnBCud

Read the full Press Release: ir.covalon.com/news/news-deta…

Join us next Wednesday, February 25, 2026, at 8:30am ET as we discuss our first quarter financial results and provide updates on our strategic progress. 📞 Investors, analysts, and stakeholders welcome 🔗 bit.ly/4c3CXA2 Link in Comments #InvestorNews #MedTech

🚀 Covalon Reports Highest Revenue Quarter of FY2025 & 3rd straight year of revenue growth! 💡 Strong commercial execution 💰 First-ever special dividend paid 📈 $32.8M global revenue & $17M cash position Onward to FY2026! Press Release Link in Comments. #MedTech #InvestorNews

Read the whole Press Release: ir.covalon.com/news/news-deta…

Join us next Thursday, December 11, at 8:30am ET as we discuss our fourth quarter financial results and provide updates on our strategic progress. 📞 Investors, analysts, and stakeholders are invited to attend. 🔗 bit.ly/4izRHb0 #InvestorNews #MedTech

Covalon has completed payment of its first ever dividend, a special C$0.15 per share milestone that reflects strong financial performance and growing global adoption. Thank you to our shareholders for their support. bit.ly/49voRGw #MedTech #InvestorNews

Read More: ir.covalon.com/news/news-deta…

Covalon has declared a $0.15 CAD special cash dividend, payable Nov 18, 2025 to shareholders on Nov 4, 2025. “With 6 straight profitable quarters, $18.9M CAD in cash, and no debt, we’re proud to reward our shareholders,” -CEO Brent Ashton. Link in Comments #InvestorNews #MedTech

Read More: 🔗 ir.covalon.com/news/news-deta…

Catch Covalon at the Planet MicroCap Showcase: TORONTO 2025! CEO Brent Ashton and Mathieu Martin will discuss Covalon’s financial strength & catalyst actions that will drive future business success. 📍 Arcadian Loft, Toronto, Oct 22,12:30 PM 🔗 Link Below #MedTech #Healthcare

“Pediatric hematology and oncology patients already face so many challenges as part of their treatment journey. The risk of blood stream infections and other largely preventable complications should not be one of them,” - Brent Ashton, CEO. Read the PR: bit.ly/46B8oxd

A peer-reviewed study on VALGuard has been published in the Journal of the Assoc. for Vascular Access (JAVA). Conducted at a prominent children’s hospital, they had a 78% reduction in CLABSIs from 2023–24, including a sustained period of 0 CLABSIs in the PCCU. Link in comments

Read More: ir.covalon.com/news/news-deta…

Covalon Q3 highlights: ✅Sequential Quarter on Quarter Revenue and Adjusted EBITDA up 10.4% and 52% respectively ✅ Trailing 12 Months Revenue increased 13% and Adjusted EBITDA up 116% Strong growth + new clinical study on the way. Thanks to our team, partners & customers! 💙

Covalon shares are now DTC eligible in the U.S., making CVALF trading easier & more accessible. This milestone boosts investor reach & strengthens our U.S. presence. Read More: bit.ly/4mpcHSZ

Join us this Thursday, August 21, at 8:30am ET as we discuss our third quarter financial results and provide updates on our strategic progress. 📞 Investors, analysts, and stakeholders are invited to attend. 🔗 bit.ly/4fWyM9j #InvestorNews #MedTech